Anthropic has launched Claude Science, an AI workbench for scientists that streamlines tools and datasets, and announced plans to develop its own drugs, focusing on neglected diseases. This move puts Anthropic in a unique position, selling software to competing drugmakers while developing its own treatments. The company’s plans are still unclear, but experts say AI is already being applied at every stage of drug discovery, from research to manufacturing. Why it matters: Anthropic’s move marks a significant shift in the AI landscape, as major companies begin to leverage AI not just as a tool, but as a driver of scientific discovery and innovation.